Lumos Diagnostics Holdings Limited (ASX:LDX) has requested a trading halt for its securities on the Australian Securities Exchange (ASX) in relation to a capital raising through a pro-rata accelerated non-renounceable entitlement offer. The trading halt is expected to remain in place until the commencement of normal trading on Friday, 6 September 2024.
The trading halt has been requested to manage continuous disclosure obligations as the company prepares to make an announcement regarding the capital raising. Lumos Diagnostics Holdings Limited expects to release the announcement to the market before the commencement of normal trading on Friday, 6 September 2024. The company has stated that it is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.
Lumos Diagnostics Holdings Limited has requested a trading halt on the ASX as it prepares to announce a capital raising through a pro-rata accelerated non-renounceable entitlement offer. The company aims to manage its continuous disclosure obligations and expects to provide the market with the announcement before the commencement of normal trading on Friday, 6 September 2024. The trading halt is set to be lifted at that time, allowing investors to react to the forthcoming announcement.